(Reuters) -BioNTech SE said on Friday it has been informed by its partner OncoC4 that the U.S. Food and Drug Administration ...

Most cases of squamous cell carcinoma can be cured when found early and treated properly. Today, many treatment options are available, and most are easily performed at a doctor’s office. Which ...

The recommended commercial dosage of UNLOXCYT is 1,200 mg administered as an intravenous infusion over 60 minutes every three weeks. Cutaneous squamous cell carcinoma (cSCC) is the second most common ...

A biopsy reveals squamous cell carcinoma (SCC) in situ. What should be the next steps in the patient's evaluation and management? After the initial consultation, the patient's biopsy specimen was ...

Surgical, radiation and medical oncologists in the Baylor St. Luke's Medical Center Dan L Duncan Comprehensive Cancer Center specialize in the diagnosis and treatment of head and neck squamous cell ...

No writing assistance was utilized in the production of this manuscript. Ocular surface squamous neoplasia is the most common nonpigmented ocular surface lesion. Ocular surface squamous neoplasia ...

Unloxcyt was approved by the FDA as a new treatment for patients with locally advanced or metastatic cutaneous squamous cell ...

UNLOXCYT (cosibelimab-ipdl) is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (“cSCC”) or locally advanced cSCC who are not candidates for curative surgery or ...

Surgery is a common treatment for non-melanoma skin cancers (NMSCs), including both basal cell cancers and squamous cell cancers. If the skin cancer is a simple lesion that’s easily treatable ...

Incyte (NASDAQ:INCY) reported positive results from a Phase 3 study of its drug Zynyz in the treatment of non-small cell lung ...

With new data on petosemtamab set to be presented at the European Society for Medical Oncology Asia Congress, Merus believes ...